NFAT inhibitor, Cell Permeable
CAS No. 592517-80-1
NFAT inhibitor, Cell Permeable( —— )
Catalog No. M30612 CAS No. 592517-80-1
NFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameNFAT inhibitor, Cell Permeable
-
NoteResearch use only, not for human use.
-
Brief DescriptionNFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
-
DescriptionNFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
-
In Vitro11R-VIVIT (100 nM) shows a significant reduction of NFAT2 expression in high glucose treated podocytes compared to podocytes treated with normal glucose. 11R-VIVIT attenuates high glucose induced filtration barrier dysfunction of podocytes.
-
In Vivo11R-VIVIT significantly abrogates the increased urinary albumin excretion rates, attenuates glomerular basement membrane (GBM) thickening and podocyte foot process effacement, partially restores podocyte number, inhibits NFAT2 activation and uPAR expression in glomerular podocytes.
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number592517-80-1
-
Formula Weight3573.15
-
Molecular FormulaC147H259N67O36S
-
Purity>98% (HPLC)
-
Solubilitywater:1 mg/mL
-
SMILES[H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Elloumi et al (2012) A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis. PLoS One 7 e34172 PMID:
molnova catalog
related products
-
Ustekinumab
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
-
Secukinumab
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
-
Kaempferitrin
Kaempferitrin has antidepressant-like effect related to the serotonergic system, principally 5-HT1A.
Cart
sales@molnova.com